<DOC>
	<DOCNO>NCT01428817</DOCNO>
	<brief_summary>Post-partum hemorrhage ( PPH ) major cause maternal death worldwide . Oxytocin common uterotonic drug use prevent treat PPH North America , however , limitation use . Oxytocin short duration action , require continuous infusion achieve sustain uterotonic activity . The Society Obstetricians Gynecologists Canada ( SOGC ) recently recommend single 100mcg dose carbetocin elective Cesarean delivery promote uterine contraction prevent post partum hemorrhage ( PPH ) , lieu traditional oxytocin regimen . Carbetocin last 4 7 time longer oxytocin , similar side effect profile apparent great efficacy rate . However , dose response determine minimum effective dose carbetocin yet publish . The investigator hypothesize minimum effective dose ( ED90 ) 20mcgs 80mcgs woman undergo elective Cesarean delivery .</brief_summary>
	<brief_title>Carbetocin Elective Cesarean Delivery Part 2</brief_title>
	<detailed_description>The Society Obstetricians Gynecologists Canada ( SOGC ) recently recommend 100mcg intravenous bolus dose carbetocin follow Cesarean delivery . Studies thus far show carbetocin may effective oxytocin promote uterine contraction , similar side effect profile . In addition , patient receive carbetocin may experience less blood loss , require less additional uterotonics compare oxytocin . A dose response study conduct Cordovani et al suggest difference efficacy uterine contraction dos carbetocin 80-120mcg . Additionally , hypotension note dose group study . The result follow-up study define minimum require dose carbetocin uterine contraction , thus minimize unnecessary side effect , improve quality safety patient care . It may also contribute establish carbetocin substitute oxytocin elective cesarean section institution well others .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Carbetocin</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>All patient plan elective cesarean delivery spinal anesthesia . All patient give write informed consent participate study . All patient refuse give write informed consent . All patient claim allergy hypersensitivity carbetocin oxytocin . All patient condition predispose uterine atony postpartum hemorrhage placenta previa , multiple gestation , preeclampsia , eclampsia , macrosomia , polyhydramnios , uterine fibroid , previous history uterine atony postpartum bleeding , bleed diathesis . All patient hepatic , renal , vascular disease , All patient require general anesthesia prior administration study drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>pregnancy</keyword>
	<keyword>postpartum hemorrhage</keyword>
	<keyword>Cesarean delivery</keyword>
	<keyword>carbetocin</keyword>
</DOC>